Clinical trial
Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic…
NCT00111475 · Amgen, Industry · Completed
Key facts
| NCT number | NCT00111475 |
|---|---|
| Title | Evaluating the Safety and Efficacy of Romiplostim (AMG 531) in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP) |
| Official title | A Dose-finding Study Evaluating the Safety and Efficacy of AMG 531 in Thrombocytopenic Subjects With Immune Thrombocytopenic Purpura (ITP) |
| Lead sponsor | Amgen, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Idiopathic Thrombocytopenic Purpura |
| Intervention type | Drug |
| Interventions | Romiplostim, Placebo |
| Enrollment | 45 |
| Start date | Jul 1, 2002 |
| Primary completion | Jun 17, 2004 |
| Completion | Jun 17, 2004 |
| First posted | May 23, 2005 |
| Last update posted | Jan 10, 2020 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: